InspirMed Inc presented data on the potential advantages of inhalable liposome formulations of antiviral drugs at the International Society for Aerosols in Medicine Congress.
InspirMed is a subsidiary of Taiwan Liposome Company (NASDAQ: TLC), specializing in developing inhalable liposome formulation programs for severe acute and chronic pulmonary diseases.
Pharmacokinetic studies on inhalable liposomal GS-441524 (ISPM21) and inhalable liposomal hydroxychloroquine (ISPM19) showed significantly higher lung concentrations than their conventional counterparts, giving the candidates the potential as prophylaxis and treatment for COVID-19.
GS-441524 is the main plasma metabolite of the antiviral prodrug remdesivir, which is approved in the US for COVID-19. GS-441524 holds several advantages over remdesivir, with better safety and efficacy profiles.
Intratracheally administered ISPM21 had a long half-life of 22.8 hours, with significantly higher concentrations (over 200-fold) in the lung and comparable systemic exposure in the plasma than an equal dose of intravenously administered GS-441524 solution.
At just 1% of the proposed oral dose of hydroxychloroquine to treat COVID-19, intratracheally administered ISPM19 had a longer half-life (around 2.5-fold) and higher exposure in the lung (~30-fold) than intravenously administered free hydroxychloroquine.
ISPM19 nebulized into an aerosol exhibited a lung deposition rate (inhaled dose) of 26.67%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.